Value to the Fore
White Paper Jan 23, 2013
Trends indicate a return to value, as Contract Research Organizations (CROs) continue to grow their skill sets and ally with the global R&D industry to tap flexible solutions aimed at improving pipeline success. Bruce Molino, Ph.D., Senior Director of Medicinal Chemistry, and Christopher Conway, Senior Director of Business Development, AMRI, analyze the increasing demand for R&D outsourcing and examine how CROs are evolving to better meet industry needs.
R&D outsourcing is widely used by pharmaceutical, biotechnology, agricultural and related industries to augment research and development and achieve objectives in a more cost effective manner. The pharmaceutical industry spends far more money on R&D outsourcing than other industries, and as a result pharmaceutical R&D budgets are an important barometer for R&D outsourcing for the broader industry looking forward. The forecast for pharmaceutical R&D spending through 2016 is estimated at about 2.5% increase per annum with a total spend in 2011 estimated around $133 billion. Prior to 2008, pharmaceutical R&D budgets increased slightly more than 10% per annum. A key reason for the slower growth forecast in R&D spending is attributed to the loss of revenue from blockbuster drugs that are losing patent protection.
Related White Papers
7 Key Factors When Considering a Benchtop X-ray DiffractometerWhite Paper
In this white paper, our marketing director of the America’s Kathy Macchiarola outlines the important decisions factors that are key requirements and help you select a benchtop system ideal for your situation and your needs.READ MORE
Supporting the Pharmaceutical Industry with 21 CFR Part 11 Compliance ReadinessWhite Paper
The purpose of this document is to describe how PANalytical systems support system owners meeting the requirements of the 21 CFR Part 11 regulations issued by the United States’ FDA.READ MORE
The Use of EDXRF for Pharmaceutical Material Elemental AnalysisWhite Paper
The recent changes to the United States Pharmacopeia (USP) regarding requirements for elemental impurity testing has peaked interest into new ways to perform this testing. Combining these new requirements with the introduction of USP chapter <735> X-ray fluorescence spectrometry1 permits a new alternate method for quantifying elemental impurities in pharmaceutical materials.READ MORE